Spectrum of Response to Platinum and PARP Inhibitors in Germline <i>BRCA</i> –Associated Pancreatic Cancer in the Clinical and Preclinical Setting
Chani Stossel(Sheba Medical Center), Talia Golan(Sheba Medical Center)
Cited by 48
Related Papers
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine
|Science|2017|1.8k
Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|502
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
|British Journal of Cancer|2014|437